Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase EARLY_PHASE1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Lung Neoplasms 10Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Brain Neoplasms 3Ureteral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma 2Oropharyngeal Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Mouth Neoplasms 2Medulloblastoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hematopoietic and Lymphatic System Neoplasm 2Glioblastoma 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2

Interventions

Radiotherapy 10Vincristine 9Dactinomycin 8Cyclophosphamide 8Radiation 6Ifosfamide 6Doxorubicin 5Irinotecan 4Filgrastim 4Etoposide 4Vinorelbine 3sargramostim 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 2Biopsy 2trofosfamide 1trioctyl phosphine oxide 1temsirolimus 1pegfilgrastim 1etoposide phosphate 1X-Rays 1Topotecan 1Surgical Procedures, Operative 1Spinal Puncture 1Sirolimus 1Sentinel Lymph Node Biopsy 1Phantoms, Imaging 1Idarubicin 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Rhabdomyosarcoma × Specimen Handling × Clear all
NCT04994132 2026-05-05

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Children's Oncology Group

Phase 3 Active not recruiting
118 enrolled
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡